• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Analyst Reiterates 'Buy' Rating on GW Pharma, Raises Price Target

February 6, 2018


Leerink Swann's Paul Matteis just reiterated his 'buy' rating on shares of GW Pharmaceuticals Plc (NASDAQ:GWPH) alongside a price target of $157.00 per share. His previous price target was $153.00 per share, and GW Pharma currently has an average price target of $171.33 per share.


With a last trade price of $126.48 for shares of GW Pharma, this price target represents over 24% potential upside. Yesterday, the company announced financial results for the first quarter ended the 31st of December, 2017. 


"With the Epidiolex regulatory applications accepted for review in both the US and Europe, and an assigned mid-year FDA decision date, 2018 is expected to be an exciting year for our Company with an anticipated first U.S. approval and launch. The commercial teams are making great progress toward launching Epidiolex with full conviction," stated Justin Gover, GW's Chief Executive Officer.


Want analyst alerts in your inbox as they're released?

Sign up for D/M/O Pro Analyst Updates here.




To sign up for GW Pharma updates, click here. Be sure to subscribe to one or more of our free e-mail newsletters so you stay up-to-date on important marijuana stock updates. Also, connect with The Daily Marijuana Observer on Facebook, Twitter, StockTwits and Instagram!

Please reload

Please reload

Please reload


© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.